CXCR2 blockade therapy also ameliorates Ang II‐induced cardiac injury [12, 13], indicating that therapies targeting inflammatory cytokines and chemokines could effectively treat Ang II‐induced cardiac hypertrophy. The gene discussed is CXCR2; the disease is cardiac hypertrophy.